Kennondale Capital Management’s Akero Therapeutics AKRO Stock Holding History

Kennondale Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,144	Closed	-$956K	–	84
2025 Q3	$956K	Buy	20,144 +6,036	+43%	+$292K	0.73%	60
2025 Q2	$753K	Hold	14,108	–	–	0.77%	51
2025 Q1	$571K	Sell	14,108 -14,109	-50%	-$598K	0.62%	62
2024 Q4	$785K	Buy	+28,217	New	+$855K	0.85%	50

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Kennondale Capital Management's AKRO Position: Q4 2025 in Review

Kennondale Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,144 shares — an estimated $956K sold.

Kennondale Capital Management first reported a position in AKRO in Q4 2024 and held it in 4 quarters. The position peaked at $956K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Kennondale Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Kennondale Capital Management sold 20,144 Akero Therapeutics shares in Q4 2025, an estimated $956K.
Kennondale Capital Management first reported a position in Akero Therapeutics in Q4 2024 and held it in 4 quarters.
Kennondale Capital Management's Akero Therapeutics position peaked at $956K in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Kennondale Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.